CHD2

STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023. The keynote session will highlight how GeneDx’s deeply curated, 20 plus year genomic dataset combined with strong research and development experience of a biopharma partner accelerates drug development programs. Amanda Singleton, Head of Biopharma and Strategic Partnerships and Vinnie Ustach, Applied Computational Biology Lead, both from GeneDx, will be joined by Jennifer Panagoulias, Chief Regulatory and Compliance Officer of Mahzi Therapeutics for the keynote lunch, “Leveraging Clinical and Genomic Data to Advance Drug Development Programs,” on Thursday, May 25, 1:30-1:50 p.m. ET. The panel will discuss how the company’s partnership with Mahzi Therapeutics has helped advance IND-enabling activities and clinical development for the company’s WWOX and CHD2-related drug candidates. “We are continuing to accelerate broad adoption of exome and genome sequencing to shorten the diagnostic odyssey for patients and empower them with a genomic-based diagnosis so they can spend less time searching for answers and more time focused on a potential treatment plan,” said Katherine Stueland, President, and Chief Executive Officer at GeneDx. “Our work with Mahzi Therapeutics is a prime example of how we are going a step further with the broader ecosystem of biopharma, using our rich genomic dataset to uncover new patient insights that are helping to advance development pipelines and bring new therapies to market for rare genetic neurodevelopmental disease candidates with no approved treatments.” “Using the GeneDx dataset, we have been able to access genomic and phenotypic data of patients otherwise not available, which has accelerated our drug development work and supported regulatory submissions and clinical program development for our WWOX and CHD2 drug candidates,” said Yael Weiss, M.D., Ph.D., Chief Executive Officer, and Founder of Mahzi Therapeutics. “We look forward to our continued partnership with GeneDx to help us deliver on our mission and bring new therapies to market for patients with rare genetic neurodevelopmental disorders.” Kareem Saad, Chief Transformation Officer at GeneDx will also participate in a panel discussion at the World Orphan Drug Congress, “Current Best Practices for Diversity in Clinical Trials: Taking a Holistic Look at Inclusivity, Outreach and Engagement” on Thursday, May 25, 12:10 p.m. - 12:50 p.m. ET. To learn more about partnering with GeneDx for biopharmaceutical, academic research, and patient advocacy collaborations, please visit . About GeneDx GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter, and Instagram. About Mahzi Therapeutics Mahzi is a private, venture-backed biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. Based on the Greek word for ‘Together’, Mahzi unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Investor Relations Contact: Tricia Truehart Investors@GeneDx.com Media Contact: Maurissa Messier Press@GeneDx.com

ORLANDO, Fla., May 3, 2023 /PRNewswire/ -- Coalition to Cure CHD2 (CCC) is pleased to announce its first-ever international research symposium and family conference to be held on June 2nd – 4th at Disney's Coronado Springs Resort in Lake Buena Vista, Florida. CCC is a nonprofit organization dedicated to supporting and advancing research in CHD2-related disorders, a rare genetic condition that can severely affect the quality of life of those living with it. Certain changes in the CHD2 gene often result in refractory epilepsy, intellectual and developmental delays, and autism. To date, no treatments exist for CHD2-related disorders, but CCC is leading the charge to change that as soon as possible. CCC's upcoming conference will bring together families, researchers, clinicians, and industry partners from all over the world to collaborate on advancing research in CHD2-related disorders. The event will host CHD2 researchers from more than six countries across three continents. The family conference portion of the event will bring together more than 100 family members and researchers from around the world to discuss and learn about the latest research in CHD2. Families in attendance will also be able to share their triumphs and struggles with each other and learn from the experts how to manage this disease. For the scientists in attendance, they will have the opportunity to meet in-person with CHD2 patients and their families to learn firsthand what it is truly like to live with this debilitating condition. CCC's international research symposium and family conference would not be possible without the endless planning hours of CCC's purely volunteer-led board of directors, and for the financial support of CCC's corporate sponsors: Mahzi Therapeutics, CURE Epilepsy, Epilepsy Alliance Florida, GeneDx, Invitae/Ciitizen, and Thisbe & Noah. Attendance at the family conference can be either in person or virtual. To view the agenda and register to attend the conference, please visit . For more information about CCC and CHD2-related disorders, please visit . SOURCE Coalition to Cure CHD2